Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development

Living medicines

Home » Health and medicine » Living medicines » Page 2

Pieter Rottiers

ActoBio Therapeutics™ CEO Pieter Rottiers on the potential to cure disease with living medicines

Jim Collins

Why now is the time for programmable living medicines: insights from Jim Collins, Aoife Brennan, and Jason Kelly

Wendell Lim

Synthetic biologist Wendell Lim talks about using living cells to raise the bar on cancer therapy

Tim Lu

Senti Biosciences’ CEO Tim Lu talks about the challenges facing cell therapies — and how we can overcome them

Synlogic Announces Achievement of Milestone in Collaboration to Develop Synthetic Biotic™ Medicines to Treat Inflammatory Bowel Disease

News digest #262 – Why 2019 is the year of living medicines + Nestlé & Codexis, + $14m for Phylagen

Ginkgo Bioworks

Living medicines: Ginkgo’s machine to disrupt the pharma industry

Synlogic

Synlogic Appoints Patricia N. Hurter, Ph.D. to Board of Directors

Living Medicines: Engineering the Microbiome

Sigilon Therapeutics and MIT Announce Research Collaboration to Advance Programmable Living Therapeutics for Serious Chronic Diseases